Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06818474 · ClinicalTrials.gov registry record · Phase 4
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
A Phase 4 study of Angioedema, sponsored by Bernstein Clinical Research Center.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT06818474: Recruiting Phase 4 study of Angioedema, sponsored by Bernstein Clinical Research Center.
NCT06818474 is a Phase 4 study of Angioedema that is actively recruiting participants, run by Bernstein Clinical Research Center. The registered enrollment target is 5 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06818474, a Phase 4 study of Angioedema, is actively recruiting participants, sponsored by Bernstein Clinical Research Center.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
use of lanadelumab in patients with acquired angioedema
Primary Outcome
Rate of investigator confirmed AAE attacks during study period, as measured by the ACT. AAE attack will be defined as a unique event during which the study subject will progress from no angioedema to symptoms of angioedema and no further angioedema for 24 hours after resolution of the event with rescu therapy
Conditions Studied
Interventions
- BIOLOGICAL Lanadelumab 300 mg
Study Locations (1)
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 4 |
What NCT06818474 shows while recruiting
NCT06818474 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Angioedema appearing as the primary indexed condition, and to 1 intervention - of which Lanadelumab 300 mg is the first listed.
NCT06818474 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06818474 about?
NCT06818474 is a clinical study titled "Lanadelumab in Long-term Prophylaxis of Acquired Angioedema". use of lanadelumab in patients with acquired angioedema
What is the current status of trial NCT06818474?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2024-06-01. Estimated completion is 2027-12-01.
What conditions does trial NCT06818474 study?
This clinical trial studies the following conditions: Angioedema.
What interventions are being tested in trial NCT06818474?
The interventions under investigation include: Lanadelumab 300 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT06818474?
This trial is sponsored by Bernstein Clinical Research Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06818474 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06818474's enrollment target sits among peer trials
5 1990th of 2000 higher than 7 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI